EP Wealth Advisors LLC Cuts Stake in DexCom, Inc. (NASDAQ:DXCM)

EP Wealth Advisors LLC reduced its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 6.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,667 shares of the medical device company’s stock after selling 197 shares during the period. EP Wealth Advisors LLC’s holdings in DexCom were worth $331,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in DXCM. DSM Capital Partners LLC purchased a new stake in DexCom during the 4th quarter worth approximately $28,000. Valley National Advisers Inc. grew its holdings in DexCom by 73.0% during the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock worth $30,000 after acquiring an additional 103 shares in the last quarter. MV Capital Management Inc. grew its holdings in DexCom by 99.3% during the 4th quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock worth $34,000 after acquiring an additional 138 shares in the last quarter. Smithfield Trust Co grew its holdings in DexCom by 103.1% during the 4th quarter. Smithfield Trust Co now owns 325 shares of the medical device company’s stock worth $40,000 after acquiring an additional 165 shares in the last quarter. Finally, Washington Trust Advisors Inc. grew its holdings in DexCom by 120.6% during the 4th quarter. Washington Trust Advisors Inc. now owns 353 shares of the medical device company’s stock worth $44,000 after acquiring an additional 193 shares in the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Stock Up 0.1 %

DXCM stock opened at $116.64 on Thursday. The company has a fifty day moving average price of $126.16 and a 200 day moving average price of $125.92. DexCom, Inc. has a 12 month low of $74.75 and a 12 month high of $142.00. The company has a market cap of $46.39 billion, a price-to-earnings ratio of 75.25, a price-to-earnings-growth ratio of 2.85 and a beta of 1.22. The company has a debt-to-equity ratio of 1.08, a current ratio of 2.90 and a quick ratio of 2.53.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.27 by $0.05. The firm had revenue of $921.00 million during the quarter, compared to the consensus estimate of $911.20 million. DexCom had a net margin of 16.82% and a return on equity of 31.01%. Sell-side analysts expect that DexCom, Inc. will post 1.78 earnings per share for the current year.

Analyst Ratings Changes

DXCM has been the subject of several analyst reports. Royal Bank of Canada initiated coverage on shares of DexCom in a report on Tuesday, March 12th. They set an “outperform” rating and a $165.00 price target for the company. UBS Group boosted their price target on shares of DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a report on Wednesday, April 10th. Redburn Atlantic assumed coverage on shares of DexCom in a report on Thursday, May 30th. They set a “neutral” rating and a $130.00 price target for the company. StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a report on Monday, June 10th. Finally, Raymond James upped their target price on shares of DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a report on Friday, April 26th. Four equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $140.94.

Insiders Place Their Bets

In other DexCom news, CEO Kevin R. Sayer sold 49,633 shares of the company’s stock in a transaction on Monday, April 8th. The shares were sold at an average price of $138.30, for a total transaction of $6,864,243.90. Following the completion of the transaction, the chief executive officer now owns 283,893 shares in the company, valued at approximately $39,262,401.90. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other DexCom news, CEO Kevin R. Sayer sold 49,633 shares of the company’s stock in a transaction on Monday, April 8th. The shares were sold at an average price of $138.30, for a total transaction of $6,864,243.90. Following the completion of the transaction, the chief executive officer now owns 283,893 shares in the company, valued at approximately $39,262,401.90. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Michael Jon Brown sold 2,624 shares of the company’s stock in a transaction on Thursday, March 28th. The stock was sold at an average price of $140.04, for a total transaction of $367,464.96. Following the transaction, the executive vice president now owns 68,682 shares of the company’s stock, valued at approximately $9,618,227.28. The disclosure for this sale can be found here. In the last quarter, insiders sold 61,837 shares of company stock worth $8,490,675. 0.30% of the stock is owned by insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.